Discovers and develops immuno-oncology products. Offers Retrocyte Display, an antibody expression platform. Now — the numbers.
This is an established company with proven profits.
An average decline of 21% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $331.9M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 2,513× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 79% of them.
Analysts' average target sits 260% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 46 buys and 0 sells. Management buying with its own money is usually read as a good sign.
Over the last 4 years, sales fell about 21% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 2513 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, AGEN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AGEN does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.